Design Therapeutics Inc. (DSGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 6005 HIDDEN VALLEY ROAD
CARLSBAD, CA 92011
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:281,800,000330,400,000384,100,000
Cash and cash equivalents21,200,00026,500,000298,569,000
Short-term investments521,196,000607,774,000170,990,000
Other undisclosed cash, cash equivalents, and short-term investments(260,596,000)(303,874,000)(85,459,000)
Receivables1,432,0001,115,000110,000
Prepaid expense1,354,0003,617,0001,254,000
Other current assets   7,000
Other undisclosed current assets(2,000)(13,000)(36,000)
Total current assets:284,584,000335,119,000385,435,000
Noncurrent Assets
Operating lease, right-of-use asset2,938,0003,612,0003,614,000
Property, plant and equipment1,691,0001,947,0001,508,000
Other undisclosed noncurrent assets430,000459,000 
Total noncurrent assets:5,059,0006,018,0005,122,000
TOTAL ASSETS:289,643,000341,137,000390,557,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,622,00010,776,0005,283,000
Accounts payable1,940,0003,025,0001,620,000
Accrued liabilities7,682,0007,751,0003,663,000
Total current liabilities:9,622,00010,776,0005,283,000
Noncurrent Liabilities
Long-term debt and lease obligation:   3,144,000
Liabilities, other than long-term debt2,334,0003,051,000 
Operating lease, liability2,334,0003,051,0003,144,000
Other undisclosed noncurrent liabilities   (3,144,000)
Total noncurrent liabilities:2,334,0003,051,0003,144,000
Total liabilities:11,956,00013,827,0008,427,000
Equity
Equity, attributable to parent277,687,000327,310,000382,130,000
Common stock6,0006,0006,000
Additional paid in capital455,245,000441,424,000429,824,000
Accumulated other comprehensive income (loss)62,000(3,356,000)(244,000)
Accumulated deficit(177,626,000)(110,764,000)(47,456,000)
Total equity:277,687,000327,310,000382,130,000
TOTAL LIABILITIES AND EQUITY:289,643,000341,137,000390,557,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Operating expenses(78,190,000)(67,593,000)(35,831,000)
Operating loss:(78,190,000)(67,593,000)(35,831,000)
Nonoperating income
(Other Nonoperating income)
11,328,0004,285,000298,000
Loss from continuing operations:(66,862,000)(63,308,000)(35,533,000)
Loss before gain (loss) on sale of properties:(35,533,000)
Net loss available to common stockholders, diluted:(66,862,000)(63,308,000)(35,533,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(66,862,000)(63,308,000)(35,533,000)
Comprehensive loss:(66,862,000)(63,308,000)(35,533,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,418,000(3,112,000)(400,000)
Comprehensive loss, net of tax, attributable to parent:(63,444,000)(66,420,000)(35,933,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: